Aranesp and Reticulocyte count increased - a phase IV clinical study of FDA data

Summary:

Reticulocyte count increased is reported as a side effect among people who take Aranesp (darbepoetin alfa), especially for people who are female, 50-59 old, have been taking the drug for 6 - 12 months also take Oxycontin, and have Anaemia.

The phase IV clinical study analyzes which people have Reticulocyte count increased when taking Aranesp. It is created by eHealthMe based on reports of 54,218 people who have side effects when taking Aranesp from the FDA, and is updated regularly.

What is Aranesp?

Aranesp has active ingredients of darbepoetin alfa. It is often used in anemia. eHealthMe is studying from 54,331 Aranesp users. Check the latest studies of Aranesp.

What is Reticulocyte count increased?

Reticulocyte count increased is found to be associated with 160 drugs and 318 conditions by eHealthMe. Check the latest studies of Reticulocyte count increased.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 28, 2026

54,218 people reported to have side effects when taking Aranesp.
Among them, 34 people (0.06%) have Reticulocyte count increased.

Could Aranesp cause Reticulocyte count increased?

Among these 34 people:

How long have people been on Aranesp when they have Reticulocyte count increased? *

What is the gender of people who have Reticulocyte count increased when taking Aranesp? *

female: 72.41 %
male: 27.59 %

What is the age of people who have Reticulocyte count increased when taking Aranesp? *

What are other drugs people take besides Aranesp? *

What are other side effects people have besides Reticulocyte count increased? *

Haemoglobin Decreased: 17 people, 50.00%
Haematocrit Decreased: 13 people, 38.24%
Fever: 12 people, 35.29%
Anaemia (lack of blood): 12 people, 35.29%
Dyspnea (difficult or laboured breathing): 12 people, 35.29%
Red Blood Cell Count Decreased: 12 people, 35.29%
White Blood Cell Count Decreased: 11 people, 32.35%
C-Reactive Protein Increased: 10 people, 29.41%
Acute Kidney Failure: 10 people, 29.41%
Depression: 10 people, 29.41%

What are the existing conditions these people have? *

Anaemia (lack of blood): 15 people, 44.12%
Musculoskeletal Pain (pain affects the bones, muscles, ligaments, tendons, and nerves): 8 people, 23.53%
Multiple Myeloma (cancer of the plasma cells): 7 people, 20.59%
Paroxysmal Nocturnal Haemoglobinuria (haemoglobin in the urine): 5 people, 14.71%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 3 people, 8.82%
High Blood Pressure: 2 people, 5.88%
Bone Marrow Disorder: 2 people, 5.88%
Breast Cancer Metastatic: 2 people, 5.88%
Chronic Kidney Disease: 2 people, 5.88%
Chronic Renal Failure (kidney failure): 2 people, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Aranesp and have Reticulocyte count increased?

- Check whether Reticulocyte count increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Aranesp:

Aranesp (54,331 reports)

Browse all side effects of Aranesp:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Reticulocyte count increased:

Reticulocyte count increased (160 drugs)

Browse all the conditions that are associated with Reticulocyte count increased:

Reticulocyte count increased (318 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on darbepoetin alfa (the active ingredients of Aranesp) and Aranesp (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.